Patient-specific cell therapies have changed the face of cancer treatment, but with price points sky high and laborious manufacturing processes, this cure is out of reach for many patients.
The 3rd annual Allogeneic Cell Therapies Summit is the only industry-focused meeting dedicated to accelerating the clinical translation of allogeneic cell therapy, to provide an affordable and accessible treatment for patients globally.
With 3 tracks of unrivalled content spanning translation, manufacturing and commercialization, join with your team to achieve next generation gene engineering to overcome rejection, improve persistence through arming and dosing, and optimize CMC and quality control to achieve long term stability at high yields and high efficacy.
200 senior level drug developers will be collaborating online this May to achieve the holy grail of allogeneic therapies. Don't miss your chance to improve your competitive intelligence and capitalize on the simplified logistics, time to delivery and reduced cost of off-the-shelf approaches.
17-19 May, 2021
9.30am-5pm EST | 6.30am-2pm PST
Drug Developers (Earlybird rates and bootcamp day available) - $2299
Academic (Earlybird rates and bootcamp day available) - $1799
Service Providers (Earlybird rates and bootcamp day available) - $2699
Drug Developers (Earlybird rates and bootcamp day available): USD 2299.0,
Academic (Earlybird rates and bootcamp day available): USD 1799.0,
Service Providers (Earlybird rates and bootcamp day available): USD 2699.0
Speakers: Sonny Hsiao, Founder and CEO, Acepodia, Nathan Yee, Associate Director, CMC Product Strategy, Allogeneic Cell Therapy, Bristol Myers Squibb, Joanna Brewer, SVP, Allogeneic Research, Adaptimmune, Tony Ho, EVP, Head of Research and Development, CRISPR Therapeutics, Barbra Sasu, CS0, Allogene, Brian Culley, CEO, Lineage Cell Therapeutics, Pascal Touchon, President and CEO, Atara Biotherapeutics, Chris Heery, CMO, Precision Biosciences
Time: 09:00 - 17:00